haloperidol and Hip Fractures

haloperidol has been researched along with Hip Fractures in 7 studies

Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.

Hip Fractures: Fractures of the FEMUR HEAD; the FEMUR NECK; (FEMORAL NECK FRACTURES); the trochanters; or the inter- or subtrochanteric region. Excludes fractures of the acetabulum and fractures of the femoral shaft below the subtrochanteric region (FEMORAL FRACTURES).

Research

Studies (7)

Authors

Clinical Trials (5)

Trial Overview

Trial Outcomes

Hematocrit (HCT)

Lab values at latest available follow-up date per participant. These tests are performed as part of routine clinical care on patients undergoing HSCT. (NCT01700816)
Timeframe: From admission to hospital to discharge, an expected average of 28 days post-transplant

Hemoglobin (HGB)

Lab values at latest available follow-up date per participant. These tests are performed as part of routine clinical care on patients undergoing HSCT. (NCT01700816)
Timeframe: From admission to hospital to discharge, an expected average of 28 days post-transplant

Hospital Length of Stay

(NCT01700816)
Timeframe: From admission to hospital to discharge, an expected average of 28 days post-transplant

Number of Participants Who Developed Delirium Based on Meeting Criteria on the Delirium Rating Scale and/or Memorial Delirium Assessment Scale

Monday, Wednesday, and Friday assessments will begin after beginning light therapy and include the Delirium Rating Scale-Revised-98 (DRS-98)and Memorial Delirium Assessment Scale (MDAS) (NCT01700816)
Timeframe: From hospital admission until the date of first documented delirium, assessed up to 28 days post-transplant

Platelet Count

Lab values at latest available follow-up date per participant. These tests are performed as part of routine clinical care on patients undergoing HSCT. (NCT01700816)
Timeframe: From admission to hospital to discharge, an expected average of 28 days post-transplant

Red Blood Cells (RBC)

Lab values at latest available follow-up date per participant. These tests are performed as part of routine clinical care on patients undergoing HSCT. (NCT01700816)
Timeframe: From admission to hospital to discharge, an expected average of 28 days post-transplant

Severity of Delirium Episodes: Memorial Delirium Assessment Scale (MDAS)

"Monday, Wednesday, and Friday assessments of the Memorial Delirium Assessment Scale (MDAS); Patients will receive assessments after beginning light therapy until day 28 post-transplant or discharge, whichever comes first.~10 item scale Items are rated on a four-point scale from 0 (none) to 3 (severe) depending on the level of impairment, rendering a maximum possible score of 30.~A score of 13 has been recommended as a cut-off for establishing the diagnosis of delirium" (NCT01700816)
Timeframe: From first documented episode of delirium until discharge from the hospital, assessed up to 28 days post-transplant

White Blood Cells (WBC)

Lab values at latest available follow-up date per participant. These tests are performed as part of routine clinical care on patients undergoing HSCT. (NCT01700816)
Timeframe: From admission to hospital to discharge, an expected average of 28 days post-transplant

Serum Creatinine and Blood Urea Nitrogen (BUN)

Lab values at latest available follow-up date per participant. These tests are performed as part of routine clinical care on patients undergoing HSCT. (NCT01700816)
Timeframe: From admission to hospital to discharge, an expected average of 28 days post-transplant

Sodium (Na), Potassium (K), Chloride (Cl), and Carbon Dioxide (CO2)

Lab values at latest available follow-up date per participant. These tests are performed as part of routine clinical care on patients undergoing HSCT (Hematopoietic Stem Cell Transplantation). (NCT01700816)
Timeframe: From admission to hospital to discharge, an expected average of 28 days post-transplant

Trials

4 trials available for haloperidol and Hip Fractures

Other Studies

3 other studies available for haloperidol and Hip Fractures